Eidos Therapeutics Inc Ipo

Eidos therapeutics inc ipo

Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.

EIDX is it a Buy (now)? IGC for Cannabis Alzheimer's, and Marijuana Mania Continues! Aug 27th

We seek to treat this well-defined family of diseases at their collective source by stabilizing TTR. Our product candidate, AG10, is an orally-administered small molecule designed to potently stabilize TTR, a potentially best-in-class treatment aiming to halt the progression of ATTR diseases.

Founded in 2013, Eidos is led by a team of industry veterans who are responsible for developing over 30 molecules through IND applications and more than 10 approved drugs.

Eidos therapeutics inc ipo

Together with patients and physicians, we aim to bring a safe, effective and disease-modifying treatment for ATTR to market as quickly as possible.